BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 162 produtos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity byFórmula:C52H57ClFN9O6Pureza:98%Cor e Forma:SolidPeso molecular:958.52GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Fórmula:C44H47N9O6Pureza:98%Cor e Forma:SolidPeso molecular:797.9QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Fórmula:C25H20ClN5O2Pureza:99.25%Cor e Forma:SoildPeso molecular:457.91BTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Fórmula:C20H25N7O2Cor e Forma:SolidPeso molecular:395.46NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Cor e Forma:SolidPeso molecular:817.94Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Fórmula:C26H26N6O3Pureza:99.98%Cor e Forma:SolidPeso molecular:470.52Anti-BTK Antibody (3G585)
Anti-BTK Antibody (3G585) is an antibody targeting BTK. Anti-BTK Antibody (3G585) can be used in ELISA, IHC.Cor e Forma:Odour LiquidZanubrutinib-d5
Zanubrutinib-d5 (BGB-3111-d5) is a deuterium-labeled Zanubrutinib, an orally available Bruton's tyrosine kinase inhibitor for the study of B-cell malignancies.Fórmula:C27H29N5O3Pureza:>99.99%Cor e Forma:SolidPeso molecular:476.58IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Fórmula:C22H23ClN6OCor e Forma:SolidPeso molecular:422.91Elsubrutinib
CAS:Elsubrutinib (ABBV-105) is an orally active, selective, and irreversible BTK inhibitor with an IC50 of 0.18 μM for the catalytic domain of BTK.Fórmula:C17H19N3O2Pureza:99.77%Cor e Forma:SolidPeso molecular:297.36GDC-0834
CAS:GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse andFórmula:C33H36N6O3SCor e Forma:SolidPeso molecular:596.74NX-5948
CAS:<p>NX-5948 (BTK-IN-24) is a PROTAC-type BTK degrader with anti-inflammatory and anticancer activities, inhibiting B cell activation.</p>Fórmula:C42H54N12O5Pureza:98.29%Cor e Forma:SolidPeso molecular:806.96N-piperidine Ibrutinib hydrochloride
CAS:N-piperidine Ibrutinib hydrochloride is a BTK inhibitor that inhibits WT BTK and C481S BTK , which inhibits the growth and proliferation of cancer cells.Fórmula:C22H23ClN6OPureza:98.83%Cor e Forma:SolidPeso molecular:422.91Tuxobertinib
CAS:Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.Fórmula:C29H29ClN6O4Pureza:99.22%Cor e Forma:SolidPeso molecular:561.03Larotinib mesylate hydrate
CAS:Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nMFórmula:C26H36ClFN4O11S2Cor e Forma:SolidPeso molecular:699.17BMS-986142
CAS:BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).Fórmula:C32H30F2N4O4Pureza:99.44% - 99.76%Cor e Forma:SolidPeso molecular:572.6Olmutinib
CAS:Olmutinib is an oral mutant-specific EGFR inhibitor for cancer treatment with potential lower toxicity.Fórmula:C26H26N6O2SPureza:99.14% - 99.63%Cor e Forma:SolidPeso molecular:486.59CGI-1746
CAS:CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.Fórmula:C34H37N5O4Pureza:97.69% - 97.88%Cor e Forma:SolidPeso molecular:579.69Ibrutinib deacryloylpiperidine
CAS:Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.Fórmula:C17H13N5OPureza:99.47%Cor e Forma:SolidPeso molecular:303.32CNX-774
CAS:CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).Fórmula:C26H22FN7O3Pureza:97.35% - 99.11%Cor e Forma:SolidPeso molecular:499.5
